Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
At a glance
- $SMMT today−9.73%last $10.67
- Vs industry peers−8.88 pts6-peer median −0.85% · far behind
- Since it broke−0.19%from the first trade after the story
- 52-week range1.3% above low$10.53 – $29.23
- Cash runway~3 mo$150.8M cash ÷ $47.2M/mo burn · 10-Q
- Coverage3 this week4 in 30 days · too few stories to call a pace
Nothing reported about summit therapeutics across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: In pharma, a regulatory or trial setback can reprice one name overnight while the rest of the sector barely notices.
- How the stock is trading: $SMMT -9.73% in the latest session.
- Timing: It was published while New York was trading, so the day's move may already include the first reaction.
Where the stock stands
Summit Therapeutics ($SMMT) slid 9.73% to $10.67 in the latest session. Over the past month it is down 31.5%. It now sits 63% under the 52-week high of $29.23 and 1.3% above the year's low of $10.53, close to the bottom of its range. It has been a volatile year: the high was 2.8 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Nov 4, 2026), $SMMT lost $208.4M over the quarter to Sep 30, 2026. Operations used $423.2M of cash over the nine months to Sep 30, 2026 — about $47.2M a month — against $150.8M in cash on Sep 30, 2026. At that pace the cash covers about 3 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $128.2M against $150.8M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 16, 1 day before this story; it is $SMMT's own account and the first thing to read. Figures are as filed with the SEC; the $SMMT page has the full statements.
How much coverage it is getting
This is one of 4 stories on Summit Therapeutics in Wook's last 30 days of coverage, including 3 this week. That is well above its usual pace: over the month it has averaged about 1 a week. Going by their wording, 0 read bullish, 2 neutral and 2 bearish. This one reads bearish, like most of them. MarketWatch wrote 2 of the 4 (50%), so the count reflects one outlet's output more than broad attention.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $SMMT page, and they say what management has disclosed without a reporter in between. Most of the recent coverage comes from one outlet, so check whether another newsroom has confirmed the story or is only repeating it. To run the numbers yourself, ask Wook AI above about $SMMT: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
MarketWatch published this on November 17, 2026. $SMMT has moved -0.19% ($10.69 to $10.67). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.